(Q40872011)

24 September 2017

title

Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia (English)

1 reference

24 September 2017

0 references

6

Tamminga CA

1 reference

24 September 2017

Lahti AC

1

1 reference

24 September 2017

Weiler MA

2

1 reference

24 September 2017

Corey PK

3

1 reference

24 September 2017

Lahti RA

4

1 reference

24 September 2017

Carlsson A

5

1 reference

24 September 2017

language of work or name

English

0 references

publication date

1 January 1998

1 reference

24 September 2017

published in

Biological Psychiatry

1 reference

24 September 2017

volume

43

1 reference

24 September 2017

issue

1

1 reference

24 September 2017

page(s)

2-11

1 reference

Negative symptoms in schizophrenia. Definition and reliability

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900030-9

Responses to apomorphine, amphetamine, and neuroleptics in schizophrenic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900030-9

Differential behavioural effects of dopamine agonists in developing rats: a study of 3-PPP enantiomers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900030-9

A Checklist for the Diagnosis of Schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900030-9

Differential electrophysiological effects of 3-PPP and its enantiomers on dopamine autoreceptors and postsynaptic receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900030-9

Bromocriptine therapy in chronic schizophrenia: effects on symptomatology, sleep patterns, and prolactin response to stimulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900030-9

Measurement of premorbid adjustment in chronic schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900030-9

The Maryland Psychiatric Research Center scale and the characterization of involuntary movements

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900030-9

Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900030-9

Dopamine receptor agonists: mechanisms underlying autoreceptor selectivity. II. Theoretical considerations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900030-9

Clinical effects of apomorphine in schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900030-9

Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900030-9

Apomorphine response and subtyping of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900030-9

Evidence for a receptor-mediated feedback control of striatal tyrosine hydroxylase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900030-9

The Schedule for the Deficit syndrome: an instrument for research in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900030-9

Affinities and intrinsic activities of dopamine receptor agonists for the hD21 and hD4.4 receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900030-9

Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900030-9

Relevance of Dopamine Autoreceptors for Psychiatry: Preclinical and Clinical Studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900030-9

B-HT 920, a dopamine D2 agonist, in the treatment of negative symptoms of chronic schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900030-9

The effect of the partial dopamine agonist terguride on negative symptoms in schizophrenics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900030-9

Dopamine Auto- and Postsynaptic Receptors: Electrophysiological Evidence for Differential Sensitivity to Dopamine Agonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900030-9

Effect of apomorphine on schizophrenic symptoms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900030-9

The prediction of outcome in schizophrenia. II. Relationships between predictor and outcome variables: a report from the WHO international pilot study of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900030-9

Suppression of exploratory locomotor activity in the rat by the local application of 3-PPP enantiomers into the nucleus accumbens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900030-9

Treatment of schizophrenia with ergot derivatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900030-9

Schizophrenic Symptoms Improve with Apomorphine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900030-9

Dopamine agonist treatment of schizophrenia with N-propylnorapomorphine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900030-9

Pharmacologic properties of (-)-3PPP (preclamol) in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900030-9

Motor effects of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900030-9

Dopaminergic neurons: An in vivo system for measuring drug interactions with presynaptic receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900030-9

10.1016/S0006-3223(97)00030-9

7 January 2021

Identifiers

DOI

1 reference

24 September 2017

1 reference